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Background: CpG hypermethylation in gene promoters is a frequent mechanism of tumor suppressor gene silencing
in various types of cancers. It usually occurs at early steps of cancer progression and can be detected easily, giving rise
to development of promising biomarkers for both detection and progression of cancer, including breast cancer.
5-aza-2′-deoxycytidine (AZA) is a DNA demethylating and anti-cancer agent resulting in induction of genes
suppressed via DNA hypermethylation.
Results: Using microarray expression profiling of AZA- or DMSO-treated breast cancer and non-tumorigenic breast
(NTB) cells, we identified for the first time TAGLN gene as a target of DNA hypermethylation in breast cancer. TAGLN
expression was significantly and frequently downregulated via promoter DNA hypermethylation in breast cancer cells
compared to NTB cells, and also in 13/21 (61.9 %) of breast tumors compared to matched normal tissues. Analyses of
public microarray methylation data showed that TAGLN was also hypermethylated in 63.02 % of tumors compared to
normal tissues; relapse-free survival of patients was worse with higher TAGLN methylation; and methylation levels could
discriminate between tumors and healthy tissues with 83.14 % sensitivity and 100 % specificity. Additionally, qRT-PCR
and immunohistochemistry experiments showed that TAGLN expression was significantly downregulated in two more
independent sets of breast tumors compared to normal tissues and was lower in tumors with poor prognosis. Colony
formation was increased in TAGLN silenced NTB cells, while decreased in overexpressing BC cells.
Conclusions: TAGLN gene is frequently downregulated by DNA hypermethylation, and TAGLN promoter methylation
profiles could serve as a future diagnostic biomarker, with possible clinical impact regarding the prognosis in
breast cancer.
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Breast cancer is the most common cancer in women,
constituting 29 % of new cancer cases estimated for
2015 in US. Breast cancer can be classified according to
molecular and histological subtypes with the most ag-
gressive behavior usually being attributed to the triple
negative (TN) subtypes, characterized with loss of estro-
gen, progesterone, and Her2 receptor expressions [1–3].
Epigenetic changes are heritable changes in gene ex-
pression patterns that do not involve alterations in the
nucleotide sequence of DNA [4]. DNA methylation is a
well-known mechanism for epigenetic gene silencing in
mammals. CpG islands are CpG-rich regions around the* Correspondence: yulug@fen.bilkent.edu.tr
1Department of Molecular Biology and Genetics, Bilkent University, Faculty of
Science, TR-06800 Ankara, Turkey
Full list of author information is available at the end of the article
© 2015 Sayar et al. Open Access This article i
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zepromoters; 5′ untranslated regions and first exons of
many genes and are usually unmethylated in normal cells
[5]. The methylated state of a CpG island usually refers to
transcriptionally repressed promoters [5]. Tumor suppres-
sor genes (TSG) may become inactivated during tumori-
genesis through hypermethylation of associated CpG
islands, providing several survival advantages [5–8].
5-aza-2′-deoxycytidine (Decitabine, AZA), a cytosine
analogue that causes covalent arrest of DNA methyltrans-
ferases (DNMT) upon binding, is one of the most com-
monly used DNMT inhibitors in cultured cells and to treat
cancer patients [9, 10]. Use of demethylating agents to-
gether with expression microarrays enables the analysis of
genes that may be regulated by hypermethylation of their
promoter regions [11]. Discovering these genes is essential
not only for therapeutic achievements but can also serve
diagnostic, prognostic, and monitoring purposes [12].s distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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is advantageous regarding the stable nature of DNA, ease
of detection, and specificity of DNA hypermethylation for
tumor cells [13]. Many known cancer-related genes like
RASSF1A, APC, BRCA1, GSTP1, and DAPK1 can be
detected from serum or blood of breast cancer patients
[14, 15]. Yet, there is still demand for novel diagnosis
markers for detection of early breast cancer. In this study,
we utilized microarray expression profiling of AZA-treated
breast cancer (BC) and non-tumorigenic breast (NTB)
cell lines, and identified TAGLN gene to be a fre-
quently hypermethylated gene and a potential future
biomarker in breast cancer.
Transgelin (TAGLN, SM22α) is an actin-binding pro-
tein that is abundantly expressed in smooth muscle cells
(SMC) [16–19]. It is downregulated in transformed fi-
broblasts and several cancer cell lines and tissues [20–24].
TAGLN gene function has been associated with increased
senescence in fibroblasts [25–27], and with increased
apoptosis in glomerular epithelial cells and prostate cancer
cells [28, 29]. TAGLN suppresses MMP9 [30], a known
element of invasion [31], and therefore prevents the
migration of colon and prostate cancer cells [32].
Controversially, it has also been found to be increased
in gastric cancer and in lymph node (LN) metastasis
of colon cancer [33, 34].
Here, we show that TAGLN is an epigenetically sup-
pressed candidate epigenetic biomarker for diagnosis in
breast cancer, by presenting its consistent downregula-
tion of expression and frequent hypermethylation in
breast carcinoma cell lines as well as in three independ-
ent breast tumor tissue cohorts. We also provide evi-
dence that TAGLN decreases the proliferation potentials
of BC and NTB cells. Better survival of breast cancer
patients with higher expression or lower promoter
methylation of TAGLN, in addition to competence of its
promoter methylation levels to discriminate cancer from
healthy tissue, emphasize a possible clinical impact for
this gene in breast cancer.
Results
Changes in the transcriptome of breast cell lines upon
AZA treatment
We treated the MCF7 and MDA-MB-231 BC cells and a
NTB cell line MCF12A with AZA or corresponding
DMSO controls before subjecting them to microarray
analysis to identify new TSG targets for promoter DNA
hypermethylation in breast cancer. Quality control ana-
lyses proved our data to be of high quality, and repli-
cates of each experiment correlated well with each other
(data not shown). Expressions of large groups of genes
were altered upon AZA treatment by 1.5-fold and above,
even at very stringent significance thresholds (Additional
file 1 and Additional file 4: Table S1). A selectionprocedure was applied to identify the genes that are al-
tered upon AZA treatment in MCF7 and MDA-MB-231
cells, but not in MCF 12A cells (Additional file 2 and
Fig. 1a). Gene lists, generated using this procedure, were
used for further analyses (Additional file 3). Probe sets
commonly or differentially altered in MCF7 and MDA-
MB-231 cell lines were also determined (Fig. 1b). We
found that 17 and 22 % of the probe sets induced in MCF7
or MDA-MB-231 cells, respectively, were induced in com-
mon while the remaining genes were cell-line specific.
Functional annotation and clustering of significantly
altered genes in either the MCF7 or MDA-MB-231 cell
lines were analyzed using the DAVID Functional Ana-
lysis Tool (Fig. 1c, d) [35, 36]. Pathways mainly involved
in mitosis and cell cycle were significantly enriched
among the downregulated genes in both of the cell lines.
Pathways related to cell communication and motility,
signal transduction, cell proliferation, and apoptosis
regulation were significantly enriched among the AZA-
induced genes in MCF7 (Fig. 1c) while regulation of
gene expression was highlighted in addition to these
pathways in MDA-MB-231 cells (Fig. 1d).
Paired t tests between seven AZA-treated and un-
treated BC cell lines of a publicly available independent
dataset (GSE20713 [37]) revealed that 53.5 % of the
probe sets that were significantly upregulated upon AZA
treatment in both MCF7 and MDA-MB-231 cells in our
experimental setup were also significantly upregulated in
the AZA-treated BC cell lines of this independent study
(P < 0.05, Additional file 4: Table S2).
Probe set lists were screened for the presence of CpG
islands in the proximity of their promoter regions, and
the induction in expression levels of several genes were
validated by qRT-PCR among the genes with proximal
CpG islands. TAGLN emerged as a strong candidate
gene among a large number of genes, as it was com-
monly and significantly upregulated upon AZA treat-
ment in both MCF7 (by 27.3-fold) and MDA-MB-231
(by 1.77-fold) cell lines (Additional file 3), and our bio-
informatics analyses showed that TAGLN expression
was significantly downregulated (>2-fold, P < 0.05) in
breast tumor tissues of 8 out of 13 (62 %) breast cancer
datasets included in Oncomine database [38] (Additional
file 4: Table S3). Moreover, TAGLN promoter region was
previously shown to be responsive to hypermethylation
in smooth muscle cells [39]. Based on these findings, we
selected this gene for further analyses.
TAGLN gene expression and promoter methylation
analyses in breast carcinoma cell lines
TAGLN gene expression was analyzed with qRT-PCR and
found to be significantly downregulated in 15 different
breast carcinoma cell lines compared to the non-
tumorigenic cell lines (P = 0.0034, Fig. 2a). The expression
Fig. 1 Analyses of AZA affected genes in BC cell lines. a The outline of the gene selection process. The numbers on the left and right represent the
probe sets obtained after the filtering process for gene selection in MCF7 and MDA-MB-231 cell lines, respectively. b Number of probe sets significantly
up/downregulated by AZA treatment, determined by the selection process given in (a). c, d DAVID analyses of Pathways affected upon AZA treatment in
MCF7 cells (c) and MDA-MB 231 cells (d). Bars represent the percentage of up- and downregulated genes involved in the indicated pathways while the
lines represent the P values for enrichment. Dashed lines indicate P= 0.05 thresholds
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Fig. 2 Expression and promoter methylation analyses of TAGLN gene in BC cell lines. a Box-plot analysis based on qRT-PCR results showing strong
downregulation of TAGLN expression in BC cell lines compared to NTB cell lines. Log2 expression levels relative to GAPDH reference gene are shown.
Horizontal dashed lines represent median values. Error bars: standard error of means (SEM). **P < 0.01; Mann–Whitney Test. b qRT-PCR analysis of
AZA-treated BC and NTB cell lines indicating high levels of induction in TAGLN expression levels. Values represent the log2 ratios of expression levels in
AZA-treated cell lines to those in their DMSO-treated cells. c QUMA software analyses based on bisulfite sequencing of BC and NTB cell lines
showing hypermethylation in TAGLN promoter in BC cells. Percent values represent the average methylation of 5 clones for each cell line.
Full circles: methylated; Empty circles: unmethylated. Sequence numbers of CpGs are shown above circles. d QUMA analysis showing significantly
higher methylation in BC cells compared to NTB; Mann–Whitney test. Methylated DNA ratio: black area; unmethylated ratio: white area in the pie chart.
e Scatter plot showing the spearman correlation of TAGLN methylation status with log2(expression) levels in BC and NTB cell lines
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AZA treatment, except for NTB cell line MCF12A
(Fig. 2b). Expression levels of TAGLN were concordant inmicroarray and qRT-PCR experiments, when fold induc-
tion levels upon AZA treatment were compared in MCF7,
MDA-MB-231, and MCF12A cell lines.
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used to characterize TAGLN methylation status in eight
BC and two NTB cell lines (Fig. 2c). The analyzed
promoter region was significantly hypermethylated in
majority of BC cell lines (with an average of 56.5 %
methylation) compared to the NTB cell lines (with an
average of 3.2 % methylation; P < 0.0001, Fig. 2d). More-
over, mRNA expression and methylation levels of TAGLN
were significantly and negatively correlated (Spearman
r = −0.927, P = 0.0003, Fig. 2e) suggesting that the
expression of TAGLN was downregulated by promoter
DNA methylation in BC cell lines.
TAGLN is downregulated by promoter hypermethylation
in human breast tumor tissues
To profile the expression and methylation status of
TAGLN in breast tumor tissues, TAGLN mRNA expres-
sion and promoter methylation levels were determined
in 21 breast tumor samples and their pair-matched nor-
mal tissues (Table 1). The expression of TAGLN was
found to be significantly downregulated in tumors com-
pared to matched normal breast tissues by qRT-PCRTable 1 Pathological features of normal matched breast tumor
tissues






#003 1 1 N/A 1 1 0
#043 0 2 N/A 1 1 1
#044 1 2 2B 0 1 1
#047 1 2 4 1 0 1
#055 0 2 N/A 1 1 1
#057 0 N/A 2B 0 0 0
#073 1 2 N/A 1 0 1
#076 1 3 2A 0 0 1
#082 0 1 2B 1 0 1
#083 1 2 2B 1 0 1
#084 1 3 N/A 0 0 0
#085 0 2 2A 0 1 1
#090 1 2 2B 1 1 1
#096 0 1 2A 0 1 0
#113 1 1 3B 1 0 1
#124 1 1 2A 1 0 1
#137 1 N/A 3A 1 1 N/A
#133 N/A N/A N/A N/A N/A N/A
#161 1 2 2A 1 0 0
#164 0 2 2B 1 1 0
#168 1 2 2B 0 1 1
ER estrogen receptor, PR progesterone receptor, Her2 Erbb2 receptor
amplification, N/A information regarding the pathological feature is missing,
1 positive for the given condition, 0 negative for the given condition(19/21 tumors, 90.5 %, P < 0.0001, Fig. 3a). The average
relative expression (ARE) ± standard error of means
(SEM) was 0.476 ± 0.1520 for normal tissues while it was
0.146 ± 0.0511 for tumor tissues, with an average de-
crease in TAGLN expression of 3.255-fold in breast
tumor tissues.
The promoter methylation status of TAGLN was ana-
lyzed via the bisulfite sequencing method, and the exam-
ined region was found to be significantly hypermethylated
in 13 (61.9 %) tumors (P < 0.05, Fig. 3b, Table 2) compared
to matched normal tissues; hypermethylation was consist-
ent across all grades (Table 2). The overall methylation
levels were also significantly higher in tumor tissues in
comparison with normals (P = 0.0263, Fig. 3c). TAGLN
mRNA expression and the promoter methylation ratios
were significantly and negatively correlated in breast
tissues (Spearman r = −0.31, P = 0.044, Fig. 3d) as in BC
cell lines, suggesting that TAGLN transcription could be
regulated by DNA methylation. We used ANLN (Anillin)
gene expression, a poor prognosis and high cellular prolif-
eration marker in breast cancer patients [40], to better
infer proliferative capacity and prognostic status of the
tumors. Expression of TAGLN was negatively (Spearman
r = −0.44, P = 0.0039) and the promoter methylation of
TAGLN was positively (Spearman r = 0.48, P = 0.0011) cor-
related with mRNA expression of ANLN gene (Fig. 3e, f).
This shows that TAGLN is likely to be downregulated
more by promoter DNA hypermethylation in breast
tumors with worse prognosis. When the tumors’
pathological features were analyzed, promoter methy-
lation, but not expression, of TAGLN was significantly
decreased in LN negative tumors when compared with
LN positives (P = 0.0476, Additional file 5: Figure S1A-B)
while both expression and methylation levels did not ex-
hibit any significant difference between grades, stages, and
hormone statuses in our tumor-normal matched breast
tissue panel.
To increase our sample size and extend our DNA
methylation analyses to a larger panel with clinical and
long-term outcome data, we downloaded the publicly
available methylation data of two independent micro-
array datasets (Super-series: GSE201713 [37], n = 247
and GSE31979 [41], n = 124), whose distributions for
methylation scores were similar, and used the normal-
ized average methylation scores (NAMS) of two probes
corresponding to TAGLN gene. In support of our
results, TAGLN probes were significantly hypermethy-
lated in breast tumors (NAMS ± SEM = 72.88 ± 0.9137,
n = 338) compared to normal tissues (NAMS ± SEM =
42.49 ± 1.541, n = 33, P < 0.0001, Fig. 4a), even though
the CpG dinucleotides corresponding to the probes were
not covered by our bisulfite primers. 83 % of the tumors
displayed higher methylation scores than the highest
score observed in the normal cohort. The average
Fig. 3 Expression and promoter methylation analyses of TAGLN gene in normal matched tumor tissues. a Box-plot analysis showing strong
downregulation in average TAGLN expression in tumor tissues compared to matched normal tissues. Log2 expression levels relative to
geometric means of ACTB and SDHA reference genes were determined by qRT-PCR. ****P < 0.0001, Wilcoxon signed rank test. b Comparative bar
charts of bisulfite sequencing based percent methylation scores of matched tumor and normal pairs showing significance hypermethylation in
majority of tumors. Methylation percentages represent the average of five clones for each tissue. Black-white bar pairs represent significant (P < 0.05)
differences between tumor and normal tissues (Wilcoxon signed rank test). Error bars represent SEM values. c Overall average methylation levels based
on QUMA were significantly higher in breast tumors compared to normal tissues; Wilcoxon signed rank test. Methylated DNA ratio; black area and
unmethylated; white area in the pie chart. d–f Scatter plots show correlations between relative TAGLN expression levels and methylation status of
TAGLN promoter in tumor and normal tissues; Spearman r = −0.3130, P = 0.0436 d; relative TAGLN and ANLN expressions; Spearman r = −0.4363;
P = 0.0039 e; and relative ANLN expression and TAGLN methylation; Spearman r = 0.4847, P = 0.0011 f. All expression values are log2. The correlations
were robust to outliers
Table 2 Frequency of TAGLN hypermethylation in tumor and normal breast tissues
Study Analyzed CpGs Cohort Hypermethylatedc Hypomethylatedd
Matched tumor tissue panel (bisulfite sequencing)a −290 to +117 All patients (n = 21) 13 (61.90 %) 4 (19.05 %)
22 CpGs Grade 1 (n = 5) 5 (100.00 %) 0 (0.00 %)
Grade 2 (n = 11) 6 (54.55 %) 3 (27.27 %)
Grade 3 (n = 2) 1 (50.00 %) 1 (50.00 %)
GSE20713 Methylation data (microarray analysis)b −571 and 455 All patients (n = 338) 213 (63.02 %) 3 (0.89 %)
2 CpGs Grade 1 (n = 64) 41 (64.06 %) 0 (0.00 %)
Grade 2 (n = 57) 35 (61.40 %) 1 (1.75 %)
Grade 3 (n = 215) 135 (62.79 %) 2 (0.01 %)
aNumber of tumors were calculated based on average methylation ratio of 22 CpGs in our normal matched tumor tissues
bNumber of tumors were calculated based on average methylation scores of two probes corresponding to two CpGs at given locations
cNumber of tumors that are significantly hypermethylated in normal matched tumor tissue panel (P < 0.05, Wilcoxon signed rank test). In microarray methylation
data, tumors with normalized average methylation score (NAMS) >30 higher than the average normal tissue NAMS were considered hypermethylated
dNumber of tumors that are significantly hypomethylated in normal matched tumor tissue panel (P < 0.05, Wilcoxon signed rank test). In microarray methylation
data, tumors with NAMS >30 lower than the average normal tissue NAMS were considered hypomethylated
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and normal tissues was 30.38; thus, the tumors with
methylation scores that were >30 higher than the aver-
age value for normal tissues were considered as hyper-
methylated. Accordingly, 63.02 % of the tumors
displayed hypermethylation of TAGLN probes in this
data set (Table 2). When grouped into tumor grades,
these ratios were at least 61.40 % for each group
(Table 2). Available expression data (GSE20711; n = 90)
of the same patients were significantly and negatively
correlated with TAGLN methylation scores (Spearman
r = −0.5442, P < 0.0001, Fig. 4b). This correlation was
preserved in each grade and pathological subtype
tested except for Luminal B (LumB) tumors, which
are known for their hypermethylator phenotypes [42]
(data not shown). Receiver-operator characteristics (ROC)
analyses of TAGLN promoter methylation showed that a
threshold of NAMS >60.94, which was derived from the
ROC analysis itself, could discriminate healthy individuals
from breast cancer patients, with 83.14 % sensitivity and
100 % specificity (area under the curve (AUC) = 0.9289,
and 95 % confidence interval (CI): 0.9027 to 0.9552,
P < 0.0001, Fig. 4c). Moreover, 10-year relapse-free
survival (RFS) of patients was significantly decreased
with higher tumor methylation of the TAGLN probes
compared to the patients with lower levels of methylationFig. 4 Methylation status of TAGLN in public datasets GSE20713 and GSE31979.
for two probes of TAGLN in tumor tissues Mann–Whitney test, ****P< 0.0001. Ho
methylation scores of TAGLN probes (GSE20713) to average expression (log2) of
analyses for discrimination between healthy individuals and breast cancer patien
higher RFS percentages for patients with tumor TAGLN NAMSs ≤80 (best cutoff(P = 0.0059, Fig. 4d). NAMSs of the TAGLN probes were
compared for different pathological features of breast
cancer, and TAGLN methylation states were similar,
independent of grade, Her2, and ER states, and sizes of
the tumors.
TAGLN mRNA and protein is downregulated in independent
sets of breast tumor tissues
To confirm downregulation of TAGLN in both protein and
mRNA levels in other independent breast tumor tissue
panels of larger sample sizes with pathological information,
expression of TAGLN was examined in a breast cancer
tissue array by IHC staining (BioChain, Cat.No:Z7020005),
and in an independent cDNA panel by qRT-PCR (Ori-
Gene, Cat.No:BCRT101). Both protein (P = 0.0116) and
mRNA expression levels (P = 0.0072) of TAGLN were sig-
nificantly downregulated in breast tumors in comparison
to non-tumor tissues (Fig. 5a, b). Average of relative
mRNA expression, ARE(mRNA) ± SEM was 0.4248 ± 0.0792
in normal tissues (n = 7) and 0.1858 ± 0.0387 in tumor tis-
sues (n = 41). Average histochemical score H-score ± SEM
was 243.6 ± 25.35 in normal tissues (n = 7), with extensive
staining in myoepithelial cells (Fig. 5a), and was 169.8 ±
9.773 in tumor tissues (n = 67). In both the tissue and
cDNA arrays, TAGLN expression was downregulated in
grade 3 tumors when compared to grade 1 and 2 tumorsa Graphs showing higher normalized average methylation scores (NAMS)
rizontal lines: mean ± SEM. b Scatter plot showing correlation of average
TAGLN probe sets (GSE20711); Spearman r=−0.5442, P< 0.0001. c ROC
ts, using TAGLN NAMSs. d Kaplan-Meier (KM) survival analysis showing
among tested)
Fig. 5 TAGLN expression in independent sets of tumor and normal breast tissues. a Examples of IHC staining of TAGLN in normal and tumor
tissues. T (red), tumor tissue; S (yellow), stroma, ×100 magnification. b–e Box-plot analyses showing significant downregulation of TAGLN mRNA
(left) and protein (right) expression levels in tumors compared to normal breast tissues (b); in grade 3 compared to grade 1 and 2 tumors (c);
progesterone receptor (PR) negative compared to positive subtypes (d); and in triple negative compared to any hormone receptor positive (ER
and/or PR and/or Her2 positive, Any positive) tumors (e). Horizontal lines: maximum, median, and minimum values. Left panels: qRT-PCR analysis
of TAGLN mRNA expression levels (log2 transformed) in a cDNA array (n = 7 normal, n = 41 tumor tissues) relative to geometric means of ACTB
and SDHA mRNA reference genes. Right panels: IHC staining of TAGLN protein in a tissue array (n = 67 tumor, n = 7 normal tissues). H-score
method was used for staining intensity calculation. *P < 0.05, **P < 0.01, Mann–Whitney Test
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in progesterone receptor PR (+) tumors (P = 0.0031 and
P = 0.0043, respectively, Fig. 5d) and in any hormone
receptor positive tumors with respect to triple negative
tumor types (P = 0.0063 and P = 0.0489, respectively,
Fig. 5e). TAGLN expression levels were not significantlydifferent in estrogen receptor (ER) or human epidermal
growth factor receptor 2 (Her2) positive or negative
tumors or in different stage groups.
The tissue panels used in this study did not have enough
information about patient survival data. KM plotter [43],
which uses public microarray expression data for survival
Sayar et al. Clinical Epigenetics  (2015) 7:104 Page 9 of 16analyses, was used to test the effect of TAGLN expression
on OS or RFS of breast cancer patients (Additional file 5:
Figure S2). There was no significant difference between
either OS or RFS of the patients based on their tumor
expression levels of TAGLN when all patient cohorts were
analyzed (Additional file 5: Figure S2A). However, when
the patients were grouped for tumor grades, higher ex-
pression of TAGLN was associated with increased OS and
RFS probabilities in patients with grade 1 and 2 tumors
(Additional file 5: Figure S2B). In grade 3 tumors, the
differences were not significant.
TAGLN decreases colony formation potentials of breast
carcinoma cell lines
Since TAGLN was frequently hypermethylated and con-
sistently downregulated in both the BC cell lines and
three independent panels of tumor tissues, we analyzed
the functional role of TAGLN in BC and NTB cells.
TAGLN gene was silenced in MCF10A and MCF12A
cells with abundant expression (Fig. 6a–c), and was over-
expressed it in MDA-MB-361 and MDA-MB-157 BC
cell lines (Fig. 6d, e) that expressed TAGLN at zero to
intermediate levels, respectively (Fig. 6a). 2D colony
formation assays were performed to test the effect of
TAGLN on proliferation potentials of these cells.
Compared to control siRNA (siCTRL), siTAGLN trans-
fected MCF10A and MCF12A cells formed significantly
(P = 0.0013 and P = 0.0016, respectively) higher number
of colonies (Fig. 6b, c, middle and lower panels). Colony
formation capabilities of MDA-MB-361 cells, but not
MDA-MB-157 cells, were significantly impaired when
they overexpressed TAGLN protein (Fig. 6d, middle and
lower panels and Fig. 6e, right panel). To examine
possible effects of TAGLN on migration and invasion
potentials of BC cells, we performed in vitro wound
healing and Matrigel invasion assays in normally motile
MDA-MB-157 cells; however, TAGLN overexpression in
these cells did not affect either wound closure or
Matrigel invasion capacities of these cells (Additional
file 5: Figure S3).
Discussion
The combination of high-throughput expression profil-
ing technology and treatment of cells with various DNA
methylation inhibitors has been widely used to discover
genome-wide effects of these drugs or to identify specific
genes involved in the related pathways. Here, we used
the same technology and identified TAGLN as an im-
portant candidate biomarker, frequently downregulated
by promoter hypermethylation in breast cancer. A recent
study (GEO ID: GSE22250) also used this method in
breast cancer [37], in which multiple breast cancer cell
lines without biological replicates were exposed to 1 μM
AZA. About half of the probe sets commonly upregulatedin BC cells by AZA treatment in our setup were also up-
regulated (P < 0.05) in the AZA-treated BC cell lines in
the aforementioned study, although they used a lower
dose (1 μM) of AZA. This indicates a potential dose
dependency of AZA treatment such that some of the
genes may require higher concentration of AZA to be
induced. However, we determined TAGLN to be up-
regulated by 2.38-fold (average of two probe sets, P < 0.05,
paired t test) also in GSE22250 study, yet this was not
reported by the authors.
The pathway analyses of 5 μM AZA-induced genes
revealed that the most significantly enriched pathways in
MCF7 cells were the cell motility, angiogenesis, cytoskel-
eton, and cell communication pathways, which could
have been suppressed in these non-motile cells under
normal conditions by DNA methylation. Yet, motility-
associated genes in invasive and motile MDA-MB-231
cells might have already been active even before the
AZA treatment, so only gene expression and protein
kinase regulation pathways were enriched upon AZA
treatment. Commonly induced pathways in both cell
lines were those relatively known as characteristics of
the AZA effect on cancer cell lines [44–47], while com-
monly downregulated pathways mostly consisted of the
cell cycle, cell division and metabolism-related pathways,
potentially resulting in cessation of cell growth and pro-
liferation when deactivated, enabling AZA’s anti-cancer
effect. Yet, most of these downregulated genes could be
possibly repressed due to secondary effects of AZA
treatment, as it caused induction of several transcription
regulatory genes.
The promoter region of TAGLN, one of the strongest
candidate genes among many probe sets, was previously
found to be methylated in hepatocellular carcinoma and
normal hepatocytes [48] and was hypermethylated in
colorectal carcinoma [49]. Using a luciferase reporter
gene construct containing the 5′-flanking region of
TAGLN promoter, and in vitro methylation of the CpG
dinucleotides within this region, Yamamura et al. [39]
showed that the transcriptional activity of TAGLN
promoter could indeed be controlled by DNA methy-
lation in smooth muscle cells. However, transcrip-
tional regulation of this gene in breast cancer has
never been studied before.
Our study is the first to document the regulation of
TAGLN gene expression by promoter hypermethylation
in both breast carcinoma cell lines and normal matched
tumor breast tissues, as well as in tumor tissues of large
set of publicly available data by means of bioinformatics
analyses. Frequent hypermethylation of the TAGLN pro-
moter region, in breast cancer even at low-grade tumors,
is comparable to the hypermethylation frequencies of
known TSGs in breast and other types of tumors [50].
High frequency of DNA hypermethylation of certain
Fig. 6 Effect of TAGLN overexpression and silencing on breast cell lines. a Western blot analysis of TAGLN in breast carcinoma and non-tumorigenic
breast cell lines. b–c Western blot shows TAGLN silencing in MCF10A (b) and MCF12A (c) cells (upper panels). 2D colony formation assays (middle and
lower panels) show increased colony formation in TAGLN silenced (siTAGLN) MCF10A (b) and MCF12A (c) cells compared to controls (siCTRL). d–e Western
blot analyses of TAGLN overexpression and subsequent colony formation assays in MDA-MB-361 (d, upper panel), and MDA-MB-157 (e, left panel) cell
clones. Overexpression of ectopic TAGLN (TAGLNvec) and levels of endogenous TAGLN (TAGLNint) were determined with TAGLN specific antibody in
clones. TAGLN overexpression caused higher cell proliferation in MDA-MB-361 cells (e), while did not affect MDA-MB-157 cells (f). Each assay was conducted
at least in quadruplicates. Two sample t test was used for comparisons. Error bars represent standard errors. **P< 0.01
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DNA from easily accessible and noninvasive sites, like
serum or plasma, of cancer patients, with quick and sen-
sitive techniques such as methylation-specific PCR
(MSP) [14, 15, 51]. Even though it is possible to detect
and analyze hypermethylated genes from the fine needle
aspirates, nipple aspirates, and ductal lavage for breast
cancer patients [52–54], diagnosis from serum or plasma
is more patient friendly and noninvasive and can be
easily repeated during the follow-up period. Thus,pursuit for blood-based tests for diagnosis of breast cancer
has been an ever expanding research area [12, 55]. The
most common biomarker candidates for detection of
breast cancer from serum is RASSF1A gene, with 100 %
specificity and 75 % sensitivity [56], and RARβ with 94 %
specificity and 87 % sensitivity [57]. Based on the high
frequency of hypermethylation in breast cancer patients
compared to healthy tissues, TAGLN promoter methyla-
tion levels can be used as an epigenetic based biomarker
for diagnosis, either alone or together with other frequent
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high sensitivity and specificity values, point out TAGLN
gene methylation as a good candidate for a tumor marker,
with 83.14 % sensitivity and 100 % specificity. These ratios
are similar to the ones obtained by combining the scores
of more than one gene for detection of breast cancer
(reviewed in Kristiansen 2013 [12]), and could increase
their competence when included in these panels. The
power of TAGLN promoter hypermethylation as an epi-
genetic diagnosis biomarker seems promising and should
be validated for detection of tumor DNA from serum,
plasma, or nipple and ductal fluids in a large, prospective
screening study.
TAGLN methylation states also relate to the prognosis
of breast cancer, as TAGLN promoter methylation levels
were negatively correlated with cellular proliferation and
worse prognosis marker ANLN expression in our tumor-
normal matched tissue panel [40]. Moreover, the prob-
ability of 10-year RFS of patients was greater with lower
TAGLN methylation scores, independent of grade, stage,
and other prognostic factors. These outcomes indicate
that hypermethylation of TAGLN promoter can also be
used as a prognostic marker. Larger cohorts of patients
with matched breast cancer and adjacent normal tissues,
and available survival information should be used to
validate these findings with bisulfite sequencing or other
sensitive techniques like MSP.
TAGLN expression was previously found to be down-
regulated in several types of cancer and transformed
cells [18, 20–22, 24]. However, studies on breast cancer
were limited to a small number of cell lines and tissues,
all of which were ductal carcinoma in situ. In this study,
we showed strong and consistent downregulation of
TAGLN mRNA and protein expression in three inde-
pendent sets of breast tumor tissues compared to non-
tumor tissues (total number of samples n = 130 tumors
and n = 35 normal tissues). Furthermore, this is the first
time an association between TAGLN expression and
breast cancer prognosis is suggested by independent
findings: (1) negative correlation of TAGLN expression
with poor prognosis marker ANLN [40]; (2) decreased
TAGLN expression particularly in triple negative breast
cancer in addition to all molecular subtypes of breast
cancer tissues; and (3) longer 10-year OS and RFS of
low-grade breast cancer patients with higher TAGLN
expression.
TAGLN is usually known as a mesenchymal protein
[19], whose expression increases with epithelial to mesen-
chymal transition (EMT) [58–60]. In this study, we found
that the expression of TAGLN was higher in grade 1 and 2
tumors compared to grade 3, suggesting that TAGLN
expression could be decreased even more when the tumor
progresses into a more undifferentiated state in breast
cancer. This suggests that downregulation of TAGLNexpression may not be related to the EMT state of breast
tumors while its downregulation can be an important
marker in breast tumor progression. Future studies with
higher numbers of grade 2 and grade 3 tumor samples will
help increase confidence in this regard.
Previous data on association of TAGLN with meta-
static states of other tumor types are also controversial.
While some studies negatively correlated TAGLN
expression with lymph node status in colon [32] and
prostate cancers [61], others found positive correlation
in colorectal cancer [34]. Increased expression of
TAGLN in metastatic nerve sheath tumors was also
shown [62]. At least part of the discrepancies in the ex-
pression levels of TAGLN in different studies has been
explained as a result of higher TAGLN expression in the
tumor stroma of invasive tumors rather than the tumor
tissue itself, which is revealed by subsequent IHC stain-
ing analyses [33, 63–65]. Accordingly, extensive staining
of TAGLN in the tumor stroma was also found in our
panel of breast tissues stained by IHC, while TAGLN
gene expression was specifically downregulated in tumor
tissues of all grades and pathological types, when com-
pared to normal tissues.
While some studies suggest a TSG function for TAGLN
due to downregulation in different types of tumors
[22, 24, 32, 49, 60, 66, 67], others define tumor-
promoting activities or overexpression in cancer [34, 68,
69]. Despite these contradictory functions suggested in
different types of tumors, our findings support a possible
tumor suppressive role of this protein in breast cancer.
The observed anti-proliferative effect exerted by TAGLN
on breast cells in our study can be caused by its close
association with the actin cytoskeleton [17, 70], which has
essential roles in several pathways in a cell (reviewed in
Hall, 2009 [71]). TAGLN expression is known to directly
affect actin cytoskeleton dynamics [60, 70, 72, 73]. In
yeast, higher expression of TAGLN homolog Scp1 de-
creases actin dynamics, leading to increased permeability
of mitochondria and release of reactive oxygen species
(ROS), which in turn results in cell death [74]. Similar re-
sults have been reported in melanoma cells [75]. Likewise,
TAGLN depletion in fibroblasts resulted in disrupted actin
organization and lower levels of ROS [60]. Thus, lower
TAGLN expression observed in breast tumors and cell
lines can support tumor development or cell proliferation
by means of decreased ROS production resulting in lon-
gevity, or other mechanisms and pathways involved, which
should be further tested in a comprehensive and focused
functional study.
TAGLN is known to be involved in SMC migration via
formation of podosomes and focal adhesions [73, 76, 77],
as well as in lung fibrosis [78]. Controversially, its overex-
pression results in decreased cellular migration in colon
cancer [32, 79]. We found that overexpression of TAGLN
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change in both the migration and invasion capabilities of
these BC cells. It is possible that TAGLN acts differently
in mesenchymal SMCs and in epithelial origin of cancer
cells, as protein profiles might differ among different cell
types, affecting the functions of individual proteins. Fur-
ther studies are required to unravel possible protein part-
ners of TAGLN in cells with different origins to explain
the contradictory outcomes observed in different studies.Conclusions
Our novel findings support the essential role of TAGLN
gene in breast cancer pathogenesis, regarding its negative
effect on cellular proliferation and its consistent downreg-
ulation in tumors. Based on substantially high methylation
frequencies in breast cancer, further studies focusing on
TAGLN promoter methylation as a diagnostic marker,
combined with other biomarkers, should seriously be
considered. These further studies with expanded breast
cancer patient cohorts and bisulfite sequencing accom-
panied with expression analyses will determine whether
TAGLN expression and/or methylation could also be used
as a prognostic marker as well.Methods
Cell culture and AZA treatment of breast cell lines
MCF7, MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-
20, BT-474, ZR-75-1, HCC1937, MDA-MB-361, MDA-
MB-157, and MCF12A cell lines were purchased from
American Type Culture Collection (ATCC). MCF10A cell
line was kindly provided by Elif Erson Bensan, (METU,
Ankara, Turkey). All cell lines were grown as recom-
mended by ATCC. AZA (5 μM, Sigma-Aldrich, A3656)
dissolved in DMSO (Applichem, A1584.0100) was used to
treat cells for 96 h, and equivalent amount of DMSO was
used as control treatment. Media was changed at every
24th hour, and cells were harvested at 96th hour.RNA isolation, determination of RNA quality and
hybridization to microchips
RNA was isolated from the cell lines with Nucleospin
RNA kit (Macherey-Nagel (MN), 740955.5), quantified
with NanoDrop ND-1000 spectrophotometer (Thermo
Scientific, USA) and the RNA integrity was determined
with Agilent 2100 Bioanalyzer (Agilent Technologies,
Germany) and all RNA samples had RNA integrity num-
ber (RIN) between 9.8–10. Hybridization of the processed
RNA samples to the gene chips (HGU-133-Plus 2.0,
Affymetrix, USA) were done following the standard Affy-
metrix protocol, in the Microarray Hybridization Facility,
at Bilkent University (Ankara, Turkey).Quality control and analysis of the microarray
expression data
Data were scanned from the microchips with GCOS
software (Affymetrix, USA). Raw data were normalized
with justRMA method using BRB-ArrayTools 3.8.0-beta,
developed by Dr. Richard Simon and the BRB-ArrayTools
Development Team (NCI, USA). Quality control and fur-
ther analyses were performed using BrB-ArrayTools. RNA
degradation plots and 3′ to 5′ signal ratios for probe sets
corresponding to ACTB and GAPDH mRNAs were calcu-
lated for quality control assessments. Class comparison
tool, which uses random variance model of t test for small
size samples, was used to find differentially expressed
genes between treatment groups. Functional annotations
were done using “Functional Annotation Chart” tool of
DAVID Bioinformatics Resources 6.7 (NIH, USA).
CDNA synthesis and quantitative RT-PCR
cDNA was synthesized from 1 μg total RNA, using oligo-
dT primers and RevertAid First Strand cDNA Synthesis
Kit (Thermo Scientific, K1622) according to user’s proto-
col. Specific primers for PCR amplification (available upon
request) were designed using PrimerBlast of NCBI [80].
qRT-PCR experiments were performed in duplicates,
using DyNAmo™ HS SYBR® Green qPCR Kit (Thermo Sci-
entific, F-410 L). GAPDH as a reference gene was tested
by calculating the significance of the log2 fold change of
multiple probe sets represented in the array. Our results
suggested that GAPDH was a reliable and stable reference
gene in response to AZA treatment in MCF7, MDA-231,
and MCF12A cell lines since no probe set exhibited fold
change greater than 1.2 fold (log2 fold change: −0.28,
FDR >0.1). Thus, GAPDH was used as an internal control
gene in cell lines, and ACTB and SDHA geometric means
were used [81] for internal control genes in tissue samples.
Delta Ct method [82] was used for relative quantification
of mRNAs, using the calculated efficiency values of each
primer pair. Statistical significance of differences between
groups was tested with Mann–Whitney test or Wilcoxon
signed rank test (for paired data), using the log2 trans-
formed expression values, using GraphPad Prism 6.0
(GraphPad Software Inc., USA).
DNA isolation, bisulfite treatment and sequencing
DNA was obtained using Nucleospin Tissue kit (Macherey-
Nagel, 740952.5) as described in the user protocol. Bilsulfite
treatment was carried out with 1 μg DNA, using Epitect
Bisulfite Kit (Qiagen, 59104). CpG islands were detected
and bisulfite sequencing primers for TAGLN gene were
designed using the Methyl Primer Express® software
(Applied Biosystems, USA). The primers amplified the
region between −290 to +117 bp with respect to TSS
(GenBank: NM_003186.3) (Left primer: 5′-GGGGTTA-
GAGAATAGTGAAGTAGGAGTA-3′; Right primer: 5′-
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tion was carried out with the QIAquick Gel extraction kit
(Qiagen, 28704). Specific PCR products were cloned into
pGEM-T-easy cloning vector (Promega, A1360) after
which plasmid isolation of selected colonies (5 for each
sample) was performed with the PureLink Quick Plasmid
Miniprep Kit (Invitrogen, K210011) and sent for sequen-
cing. Sequencing of the bisulfite-treated DNA inserts was
performed with SP6 primers using the dideoxy chain ter-
mination method (by Iontek, Istanbul, Turkey). Bisulfite
sequencing results were analyzed using QUMA software
[83]. Statistical differences between breast cancer and
NTB cell lines were tested with Mann–Whitney test. Stat-
istical differences between methylation percentages of
paired tissues were tested with Wilcoxon signed rank test,
in GraphPad Prism 6.0.
Breast tumors and normal tissue samples
TAGLN expression in publicly available datasets was
analyzed using Oncomine™ (Compendia Bioscience, USA).
Primary breast tumors and their matched normal tissues
(Table 1) were surgically removed from patients (n = 21), at
Numune Training and Research Hospital, Ankara, Turkey.
The use of the tissue material in this project was approved
by the Ethics Committee and consents were obtained in
accordance with the Helsinki Declaration of 1975. Tumor
samples used in the study were composed >90 % of tumor
cells, according to hematoxylin and eosin staining.
RNA isolation from tissues was performed with Trizol
(Life Technologies, 15596–026). Breast tumor cDNA array
(OriGene, BCRT101) was composed of 41 tumor and 7
normal tissues. Breast tumor tissue array (BioChain,
Z7020005) was composed of 7 non-tumor and 68 tumor
tissues of breast.
IHC staining and scoring
Immunohistochemical studies were performed automatic-
ally in the Bond Max equipment (Leica Microsystems Inc.).
Antigen retrieval steps were performed in Bond-Epitope
Retrieval Solution 1 (Leica Microsystems, Germany)
with TAGLN antibody (1:500, Abcam ab1416) at 100 °C.
Detection was carried out with Bond Polymer Refine Red
Detection kit (Leica Microsystems, DS9390). Stained slides
were dehydrated and covered with mounting medium
(Dako, CS70330) and cover-slips. Digital images of the
slides were evaluated using the H-score method [84].
Statistical differences between groups were calculated with
Mann–Whitney test while correlations were tested with
Spearman correlation, in GraphPad Prism 6.0.
Survival analysis and analysis of publicly available
methylation data
Survival analyses regarding the expression of TAGLN were
performed using Kaplan-Meier (KM) plotter, breast cancercohort [43]. Gene expression information of 205547_s_at
probe set corresponding to TAGLN was used. Auto cutoff
was used to generate the best performing KM curves. To
perform methylation analyses, all the methylation data
published under super-series GSE20713 (GSE20712 and
GSE22249) and a separate dataset (GSE31979), whose
data distributions were similar, were downloaded from
GEO2R. Both of the studies were performed on GPL8490
Illumina HumanMethylation27 BeadChip arrays. One
probe (cg24619694) corresponded to a CpG at +445 pos-
ition from TSS of TAGLN, and the other probe
(cg06950730) corresponded to a CpG at −561 position.
Methylation scores of two probes were correlated (Spear-
man coefficient = 0.714, P < 0.0001). Thus, average methy-
lation scores of the two probes were used for the
calculations. The data were normalized by assigning 0 for
the lowest average methylation scores for two probes of
TAGLN gene, and assigning the value 100 for the highest
scores for each dataset, and the scores in between are fit
into a sigmoidal curve. Normalized methylation scores
(NAMS) were used for the further studies. Mann–
Whitney test was used to compare two groups. For
correlation analyses, expression data (GSE20711) cor-
responding to 88 breast cancer patients and 2 healthy in-
dividuals included in the methylation study (GSE20713)
was downloaded from GEO2R, and the Spearman’s rank
correlation between expression and methylation scores
was calculated. For survival analyses using the NAMS
values, a range of values greater than or equal to the diag-
nostic cutoff (i.e., 60, 65, 70, 75, 80, 85, and 90) was tested,
and the best performing cutoff was determined to be
NAMS >80 [85]. Patients were divided into NAMS ≥80
and NAMS <80 groups, and 10-year RFS were calcu-
lated for each group. P values were calculated using
Gehan-Breslow-Wilocoxon test in GraphPad Prism 6.0.
Western blotting
Protein lysates (20–50 mg) from cell lines were separated
under reducing conditions (5 % β-mercaptoethanol), in
12 % Tris-glycine gels and SDS-Tris-glycine running buffer
and were blotted on nitrocellulose membranes. Membranes
were incubated overnight at 4 °C, with primary antibodies
(α-TAGLN, Abcam ab1416, 1:2,000; α-Calnexin, Abcam,
1:20,000), followed by washing with Tris buffered saline –
Tween-20 (0.25 %, TBS-T) and secondary antibody (horse
radish peroxidase-conjugated anti-rabbit IgG, Abcam
1:5,000) incubations for 1 h at room temperature. Sig-
nal detection was performed with ECL prime system
(Amersham Life Science, RPN2232).
siRNA transfections and overexpression of TAGLN in breast
cancer cells
siGENOME Human TAGLN siRNA (SMARTpool,
Thermo Scientific, M-003714-02-0020) and siGENOME
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02-20) control siRNA transfections were performed with
RNAi-max (Invitrogen, 13778150), using the reverse
transcription protocol supplied by the producer. TAGLN
overexpression, TrueORF-Gold pCMV6-Entry-TAGLN
(Origene, RC215789), and control pCMV6-Entry vectors
(Origene, PS100001) were transfected to MDA-MB-361
and MDA-MB-157 cells using Lipofectamine 2000 reagent
(Invitrogen, 11668019). Stable clones were generated with
Geneticin (Gibco-Life Technologies, 10131–035) selection.
2D colony formation assays
Cells were seeded to be 2.000/well in 6-well plates and
were grown for 2 weeks (MDA-MB-157, MCF10A, and
MCF12A) or for 4 weeks (MDA-MB-361). Colonies were
then stained with 0.5 % crystal violet and counted using
Image J (NIH). Colony sizes of MDA-MB-361 were calcu-
lated using Image J. Colony sizes of other cell lines could
not be determined due to more scattered nature of col-
onies of these mesenchymal types of cells. Statistical differ-
ences were calculated with two sample t test in GraphPad
Prism 6.0.
In vitro wound healing and Matrigel invasion assays
For in vitro wound healing assays, cells were plated to be
confluent in 24-well plates. Next day, media was changed
to low serum media (0.5 % FBS) and at least 6 independ-
ent scratches/sample were made with 200-μl pipette tips,
and photos were taken after 24 h. Statistical differences
between groups were tested with the Mann–Whitney test
in GraphPad Prism 6.0. For Matrigel invasion assays,
Growth Factor Reduced Matrigel Matrix Basement
Membrane (BD, 356230) was diluted (1:5) and added to
Transwell Permeable Support invasion chambers (Corn-
ing, 3422) in 24 wells to form a thin layer. Cells (150,000)
per chamber were added to the upper chamber with 0.5 %
serum containing media and the lower chamber was sup-
plied with 10 % serum containing medium. Cells on the
lower side of the chamber were stained with Giemsa and
counted at the 48th hour.
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